<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01187498</url>
  </required_header>
  <id_info>
    <org_study_id>B3083-R</org_study_id>
    <nct_id>NCT01187498</nct_id>
  </id_info>
  <brief_title>Behavioral Treatment of Overactive Bladder in Men</brief_title>
  <acronym>MOTIVE</acronym>
  <official_title>Behavioral Treatment of Overactive Bladder in Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this project is to evaluate the effectiveness of behavioral treatment
      compared to standard drug therapy for symptoms of OAB in male veterans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overactive bladder (OAB) is a very common and bothersome condition manifested by urgency,
      frequent urination, urge urinary incontinence, and nocturia. Drug therapy with oxybutynin or
      tolterodine is the most common approach to treatment of OAB in VA Medical Center clinics and
      is the standard of care nationally. Although it improves symptoms of OAB for many patients,
      drug therapy often has side effects, which cause a significant number of patients to
      discontinue therapy. Further, many symptoms are not completely controlled, even while
      patients are on the medication. Therefore, there is a need to improve interventions for this
      common problem. Although behavioral treatment is a well-established treatment for urge
      urinary incontinence and frequency in women, there are no controlled trials of behavioral
      treatment for symptoms of OAB in men. The primary purpose of this project is to evaluate the
      effectiveness of behavioral treatment for symptoms of OAB in male veterans.

      The study is a two-site (Birmingham and Atlanta) randomized clinical trial to evaluate the
      effects of behavioral training compared to a standard (drug) treatment control condition.
      Subjects are 143 men with OAB as manifested by urgency and frequent urination (&gt;8 voids per
      day), with or without incontinence, and without significant bladder outlet obstruction.
      Following a run-in period in which all patients are treated with an alpha blocker to
      empirically treat any undetected obstruction, they are stratified on severity and presence of
      urge incontinence and randomized to 8 weeks of behavioral treatment or drug therapy. The
      behavioral treatment is a comprehensive, behavioral training program, which includes pelvic
      floor muscle rehabilitation, self monitoring with bladder diaries, and teaching urge
      suppression and other skills to inhibit detrusor contraction, thus reducing urgency,
      frequency, incontinence, and nocturia. Patients in the control group receive standard therapy
      consisting of individually titrated, extended-release oxybutynin, a well-established
      pharmacologic agent with a state of the art drug delivery system that has the lowest rates of
      side effects. Bladder diaries completed by subjects prior to randomization and following the
      last treatment session are used to calculate changes in frequency of urination, as well as
      other symptoms of overactive bladder, including reports of urgency, incontinence, and
      nocturia. Secondary outcome measures include patient global ratings of satisfaction and
      improvement, impact of incontinence, and the American Urological Association (AUA) Symptom
      Index.

      The second purpose of the study is to examine combined behavioral and drug therapy. Following
      post-treatment assessment, patients who do not achieve satisfactory outcomes with either
      behavioral or drug therapy alone are crossed over into a second phase, in which they receive
      combined treatment to improve outcome as much as possible.

      This study will yield important information related to alternative treatment of OAB in male
      veterans. Though many clinicians use drug therapy routinely in the treatment of OAB, most do
      not offer behavioral treatments such as pelvic floor muscle training for this problem. Thus,
      this study has potential to alter standards of care for OAB in men.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-hour Voiding Frequency</measure>
    <time_frame>post-treatment (week 8)</time_frame>
    <description>Mean voiding frequency per 24 hours derived from 7-day bladder dairy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Nocturia Frequency</measure>
    <time_frame>baseline to post-treatment (week 8)</time_frame>
    <description>Change in frequency of nocturia episodes based on 7-day bladder diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urgency Severity</measure>
    <time_frame>baseline to post-treatment (week 8)</time_frame>
    <description>Indevus Urgency Severity Scale incorporated into the 7-day bladder diary. Scores for urgency severity ranged from 0 to 3:
0: None—no urgency
Mild—awareness of urgency, but is easily tolerated.
Moderate—enough urgency discomfort that it interferes with or shortens usual activity
Severe—extreme urgency discomfort that abruptly stops all activities or tasks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Frequency of Urge Incontinence</measure>
    <time_frame>baseline to post-treatment (week 8)</time_frame>
    <description>Percent change in frequency of urge incontinence episodes based on 7-day bladder diary. Percent change was calculated as ([frequency at baseline] - [frequency at 8 weeks]) / (frequency at baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on American Urological Association (AUA) Symptom Index</measure>
    <time_frame>baseline to post-treatment (week 8)</time_frame>
    <description>Change in score on American Urological Association (AUA) Symptom Index (baseline to week 8). The index measures lower urinary tract symptoms. Scores range from 0 to 35, with higher scores indicating worse symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Perception of Improvement (GPI)</measure>
    <time_frame>post-treatment (week 8)</time_frame>
    <description>Patient global perception of improvement (&quot;much better&quot; to &quot;much worse&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>post-treatment (week 8)</time_frame>
    <description>Patient global rating of satisfaction with progress in treatment (&quot;completely satisfied&quot; to &quot;very dissatisfied&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Rating of Activity Restriction</measure>
    <time_frame>post-treatment (week 8)</time_frame>
    <description>Patient global rating of activity restriction (&quot;not at all&quot; to &quot;all the time&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Report of Symptom Distress</measure>
    <time_frame>post-treatment (week 8)</time_frame>
    <description>Patient report of how disturbed they were by symptoms (&quot;not at all&quot; to &quot;extremely&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Rating of Bothersomeness of Side Effects</measure>
    <time_frame>post-treatment (week 8)</time_frame>
    <description>Patient global rating of how bothersome their side effects were (&quot;no side effects&quot; to &quot;extremely bothersome&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Desire for Alternate Treatment</measure>
    <time_frame>post-treatment (week 8)</time_frame>
    <description>Patient response to &quot;Do you wish to receive another form of treatment?&quot; (yes)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">143</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Behavioral Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Behavioral training using delayed voiding, urge suppression techniques, and pelvic floor muscle training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxybutynin chloride, extended-release, individually-titrated, 5-30 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral training</intervention_name>
    <description>Comprehensive behavioral training program using delayed voiding, urge suppression techniques, pelvic floor muscle training, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.</description>
    <arm_group_label>Behavioral Training</arm_group_label>
    <other_name>Behavioral treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxybutynin chloride, extended-release</intervention_name>
    <description>Individually titrated, extended-release oxybutynin chloride, initiated at 10 mg, fluid management handout, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.</description>
    <arm_group_label>Drug Therapy</arm_group_label>
    <other_name>Antimuscarinic medication</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  Community-dwelling

          -  Veteran

          -  Self-reported urgency

          -  Self-reported frequent urination

          -  Mean of &gt; 8 voids per 24-hour day on bladder diary

          -  Able to come to clinic

        Exclusion Criteria:

          -  Urologic surgery in the past 6 months

          -  Nonambulatory (unless has independent transfer skills)

          -  Flow rate &lt; 5mL at baseline and &lt; 10mL/sec after run-in (on simple uroflowmetry)

          -  Post-void residual urine volume &gt; 250mL at baseline and &gt; 150mL after run-in (on
             bladder ultrasound)

          -  Continual leakage

          -  Urinary tract infection (growth of &gt; 100,000 colonies per ml of a urinary pathogen on
             urine culture). May be reconsidered after treatment and negative culture.

          -  Fecal impaction

          -  Poorly controlled diabetes (glycosylated hemoglobin &gt;9 within last 3 months)

          -  Hematuria on microscopic examination in the absence of infection

          -  Any unstable medical condition (particularly: decompensated congestive heart failure,
             malignant arrhythmias, unstable angina)

             -- Impaired mental status (&lt; 24 on Folstein's Mini-Mental State Exam)

          -  Narrow angle glaucoma

          -  Gastric retention (by medical history)

          -  Hypersensitivity to tamsulosin or oxybutynin

          -  Current use of anticholinergic agents for detrusor instability. May be reconsidered
             after 2-week wash-out.

          -  If on diuretic, dose has not been stable for at least three months

          -  Sleep apnea, unless surgically corrected
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn L. Burgio, PhD MA BA</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Office of Research and Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham VA Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta VA Medical and Rehab Center, Decatur</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Burgio KL, Goode PS, Johnson TM, Hammontree L, Ouslander JG, Markland AD, Colli J, Vaughan CP, Redden DT. Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial. J Am Geriatr Soc. 2011 Dec;59(12):2209-16. doi: 10.1111/j.1532-5415.2011.03724.x. Epub 2011 Nov 7.</citation>
    <PMID>22092152</PMID>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2010</study_first_submitted>
  <study_first_submitted_qc>August 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2010</study_first_posted>
  <results_first_submitted>October 28, 2013</results_first_submitted>
  <results_first_submitted_qc>April 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 20, 2014</results_first_posted>
  <last_update_submitted>April 22, 2014</last_update_submitted>
  <last_update_submitted_qc>April 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Overactive bladder</keyword>
  <keyword>Behavioral treatment</keyword>
  <keyword>Drug therapy</keyword>
  <keyword>Lower urinary tract symptoms</keyword>
  <keyword>Urinary incontinence</keyword>
  <keyword>Clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxybutynin</mesh_term>
    <mesh_term>Mandelic Acids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited through mailed surveys about bladder symptoms and through clinics at two Veterans Affairs Medical Centers(2005–2009).</recruitment_details>
      <pre_assignment_details>To minimize possible effect of undetected obstruction we used a 4-week alpha-blocker run-in (tamsulosin 0.4 mg/d or alternative). Participants who continued to meet inclusion criteria after run-in were randomized. Alpha-blocker therapy was continued throughout the trial, unless not tolerated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Behavioral Training</title>
          <description>Delayed voiding, urge suppression techniques, pelvic floor muscle training</description>
        </group>
        <group group_id="P2">
          <title>Drug Therapy</title>
          <description>Individually titrated, extended-release oxybutynin chloride, 5-30mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Behavioral Training</title>
          <description>Delayed voiding, urge suppression techniques, pelvic floor muscle training</description>
        </group>
        <group group_id="B2">
          <title>Drug Therapy</title>
          <description>Individually titrated, extended release oxybutynin chloride</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="73"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="143"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.7" spread="10.3"/>
                    <measurement group_id="B2" value="64.8" spread="9.6"/>
                    <measurement group_id="B3" value="64.2" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>24-hour Voiding Frequency</title>
        <description>Mean voiding frequency per 24 hours derived from 7-day bladder dairy</description>
        <time_frame>post-treatment (week 8)</time_frame>
        <population>Treatment completers</population>
        <group_list>
          <group group_id="O1">
            <title>Behavioral Training</title>
            <description>Delayed voiding, urge suppression techniques, pelvic floor muscle training</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy</title>
            <description>Individually titrated, extended release oxybutynin chloride</description>
          </group>
        </group_list>
        <measure>
          <title>24-hour Voiding Frequency</title>
          <description>Mean voiding frequency per 24 hours derived from 7-day bladder dairy</description>
          <population>Treatment completers</population>
          <units>voids per 24-hour day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="2.5"/>
                    <measurement group_id="O2" value="9.5" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis was an equivalence analysis to compare the two treatment groups on posttreatment 24- hour voiding frequency using a margin of ±15% of the drug group mean. Schuirmann’s two one-sided tests (TOST) approach was used first to examine completers and then repeated using last observation carried forward to include participants who did not complete therapy. Adjusting the test to regression, the analyses were repeated using baseline voiding frequency as a covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A power analysis indicated that a sample size of 70 per group would provide 80% power with a one-sided alpha of 0.05 to declare two means equivalent, assuming a mean voiding frequency of 8.2 for behavioral treatment, a mean voiding frequency of 8.0 for drug therapy, and a standard deviation of 2.3 for both groups. Equivalence was defined as ±15% of the drug therapy posttreatment mean.</non_inferiority_desc>
            <p_value>.001</p_value>
            <method>Regression, Linear</method>
            <param_type>Difference of the Means</param_type>
            <param_value>.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.346</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The estimated parameter of dispersion is the standard error of the regression coefficient which measured the adjusted difference of the group means.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Nocturia Frequency</title>
        <description>Change in frequency of nocturia episodes based on 7-day bladder diary</description>
        <time_frame>baseline to post-treatment (week 8)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Behavioral Training</title>
            <description>Delayed voiding, urge suppression techniques, pelvic floor muscle training</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy</title>
            <description>Individually titrated, extended release oxybutynin chloride</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Nocturia Frequency</title>
          <description>Change in frequency of nocturia episodes based on 7-day bladder diary</description>
          <units>nocturia episodes per night</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread=".72"/>
                    <measurement group_id="O2" value="-.32" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Standard regression methods adjusting for baseline values</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.05</p_value>
            <method>Regression, Linear</method>
            <param_type>Difference of the Means</param_type>
            <param_value>-.38</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.188</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The estimated parameter of dispersion represents the standard error for the difference of the group means.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Urgency Severity</title>
        <description>Indevus Urgency Severity Scale incorporated into the 7-day bladder diary. Scores for urgency severity ranged from 0 to 3:
0: None—no urgency
Mild—awareness of urgency, but is easily tolerated.
Moderate—enough urgency discomfort that it interferes with or shortens usual activity
Severe—extreme urgency discomfort that abruptly stops all activities or tasks.</description>
        <time_frame>baseline to post-treatment (week 8)</time_frame>
        <population>Participants who completed treatment and returned bladder diary with useable urgency scores</population>
        <group_list>
          <group group_id="O1">
            <title>Behavioral Training</title>
            <description>Delayed voiding, urge suppression techniques, pelvic floor muscle training</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy</title>
            <description>Individually titrated, extended release oxybutynin chloride</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urgency Severity</title>
          <description>Indevus Urgency Severity Scale incorporated into the 7-day bladder diary. Scores for urgency severity ranged from 0 to 3:
0: None—no urgency
Mild—awareness of urgency, but is easily tolerated.
Moderate—enough urgency discomfort that it interferes with or shortens usual activity
Severe—extreme urgency discomfort that abruptly stops all activities or tasks.</description>
          <population>Participants who completed treatment and returned bladder diary with useable urgency scores</population>
          <units>Score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".04" spread=".58"/>
                    <measurement group_id="O2" value="-.15" spread=".42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Standard regression methods adjusting for baseline values</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of Group Means</param_type>
            <param_value>0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.091</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The estimated parameter of dispersion represents the standard error for the difference of the group means.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Frequency of Urge Incontinence</title>
        <description>Percent change in frequency of urge incontinence episodes based on 7-day bladder diary. Percent change was calculated as ([frequency at baseline] - [frequency at 8 weeks]) / (frequency at baseline).</description>
        <time_frame>baseline to post-treatment (week 8)</time_frame>
        <population>Included participants who experienced incontinence at baseline only</population>
        <group_list>
          <group group_id="O1">
            <title>Behavioral Training</title>
            <description>Delayed voiding, urge suppression techniques, pelvic floor muscle training</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy</title>
            <description>Individually titrated, extended release oxybutynin chloride</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Frequency of Urge Incontinence</title>
          <description>Percent change in frequency of urge incontinence episodes based on 7-day bladder diary. Percent change was calculated as ([frequency at baseline] - [frequency at 8 weeks]) / (frequency at baseline).</description>
          <population>Included participants who experienced incontinence at baseline only</population>
          <units>Percent change in episodes per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.2" spread=".25"/>
                    <measurement group_id="O2" value="75.6" spread=".36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Standard regression methods adjusting for baseline values</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.33</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference in Group Means</param_type>
            <param_value>-.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.091</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The estimated parameter of dispersion represents the standard error for the difference of the group means.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change on American Urological Association (AUA) Symptom Index</title>
        <description>Change in score on American Urological Association (AUA) Symptom Index (baseline to week 8). The index measures lower urinary tract symptoms. Scores range from 0 to 35, with higher scores indicating worse symptoms.</description>
        <time_frame>baseline to post-treatment (week 8)</time_frame>
        <population>Completers</population>
        <group_list>
          <group group_id="O1">
            <title>Behavioral Training</title>
            <description>Delayed voiding, urge suppression techniques, pelvic floor muscle training</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy</title>
            <description>Individually titrated, extended release oxybutynin chloride</description>
          </group>
        </group_list>
        <measure>
          <title>Change on American Urological Association (AUA) Symptom Index</title>
          <description>Change in score on American Urological Association (AUA) Symptom Index (baseline to week 8). The index measures lower urinary tract symptoms. Scores range from 0 to 35, with higher scores indicating worse symptoms.</description>
          <population>Completers</population>
          <units>Scores on the scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="4.6"/>
                    <measurement group_id="O2" value="3.2" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Standard regression methods adjusting for baseline values</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.84</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.924</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The estimated parameter of dispersion represents the standard error for the difference of the group means.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Perception of Improvement (GPI)</title>
        <description>Patient global perception of improvement (&quot;much better&quot; to &quot;much worse&quot;)</description>
        <time_frame>post-treatment (week 8)</time_frame>
        <population>Completers minus one missing value</population>
        <group_list>
          <group group_id="O1">
            <title>Behavioral Training</title>
            <description>Delayed voiding, urge suppression techniques, pelvic floor muscle training</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy</title>
            <description>Individually titrated, extended release oxybutynin chloride</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Perception of Improvement (GPI)</title>
          <description>Patient global perception of improvement (&quot;much better&quot; to &quot;much worse&quot;)</description>
          <population>Completers minus one missing value</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>About the same</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cochran Mantel-Haenszel procedure used to account for the ordinal nature of responses.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.69</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in Weighted Group Means</param_type>
            <param_value>-.0563</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.1249</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The estimated parameter of dispersion represents the standard error for the difference of the weighted group means.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction</title>
        <description>Patient global rating of satisfaction with progress in treatment (&quot;completely satisfied&quot; to &quot;very dissatisfied&quot;)</description>
        <time_frame>post-treatment (week 8)</time_frame>
        <population>Completers minus one missing value</population>
        <group_list>
          <group group_id="O1">
            <title>Behavioral Training</title>
            <description>Delayed voiding, urge suppression techniques, pelvic floor muscle training</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy</title>
            <description>Individually titrated, extended release oxybutynin chloride</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction</title>
          <description>Patient global rating of satisfaction with progress in treatment (&quot;completely satisfied&quot; to &quot;very dissatisfied&quot;)</description>
          <population>Completers minus one missing value</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Completely satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cochran Mantel-Haenszel procedure used to account for the ordinal nature of responses.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.16</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference between Group Weighted Means</param_type>
            <param_value>-.1563</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1009</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The estimated parameter of dispersion represents the standard error for the difference of the weighted group means.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Rating of Activity Restriction</title>
        <description>Patient global rating of activity restriction (&quot;not at all&quot; to &quot;all the time&quot;)</description>
        <time_frame>post-treatment (week 8)</time_frame>
        <population>Com0leters minus one missing value</population>
        <group_list>
          <group group_id="O1">
            <title>Behavioral Training</title>
            <description>Delayed voiding, urge suppression techniques, pelvic floor muscle training</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy</title>
            <description>Individually titrated, extended release oxybutynin chloride</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Rating of Activity Restriction</title>
          <description>Patient global rating of activity restriction (&quot;not at all&quot; to &quot;all the time&quot;)</description>
          <population>Com0leters minus one missing value</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some of the time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All the time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cochran Mantel-Haenszel procedure used to account for the ordinal nature of responses.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.56</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in Weighted Group Means</param_type>
            <param_value>0.1079</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.1625</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The estimated parameter of dispersion represents the standard error for the difference of the weighted group means.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Report of Symptom Distress</title>
        <description>Patient report of how disturbed they were by symptoms (&quot;not at all&quot; to &quot;extremely&quot;)</description>
        <time_frame>post-treatment (week 8)</time_frame>
        <population>Completers minos one missing value</population>
        <group_list>
          <group group_id="O1">
            <title>Behavioral Training</title>
            <description>Delayed voiding, urge suppression techniques, pelvic floor muscle training</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy</title>
            <description>Individually titrated, extended release oxybutynin chloride</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Report of Symptom Distress</title>
          <description>Patient report of how disturbed they were by symptoms (&quot;not at all&quot; to &quot;extremely&quot;)</description>
          <population>Completers minos one missing value</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All the time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cochran Mantel-Haenszel procedure used to account for the ordinal nature of responses.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.65</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in Weighted Group Means</param_type>
            <param_value>0.0540</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.1265</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The estimated parameter of dispersion represents the standard error for the difference of the weighted group means.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Rating of Bothersomeness of Side Effects</title>
        <description>Patient global rating of how bothersome their side effects were (&quot;no side effects&quot; to &quot;extremely bothersome&quot;)</description>
        <time_frame>post-treatment (week 8)</time_frame>
        <population>Completers minus one missing value</population>
        <group_list>
          <group group_id="O1">
            <title>Behavioral Training</title>
            <description>Delayed voiding, urge suppression techniques, pelvic floor muscle training</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy</title>
            <description>Individually titrated, extended release oxybutynin chloride</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Rating of Bothersomeness of Side Effects</title>
          <description>Patient global rating of how bothersome their side effects were (&quot;no side effects&quot; to &quot;extremely bothersome&quot;)</description>
          <population>Completers minus one missing value</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No side effects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not at all bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Little</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cochran Mantel-Haenszel procedure used to account for the ordinal nature of responses.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.01</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Desire for Alternate Treatment</title>
        <description>Patient response to &quot;Do you wish to receive another form of treatment?&quot; (yes)</description>
        <time_frame>post-treatment (week 8)</time_frame>
        <population>Completers minus one missing value</population>
        <group_list>
          <group group_id="O1">
            <title>Behavioral Training</title>
            <description>Delayed voiding, urge suppression techniques, pelvic floor muscle training</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy</title>
            <description>Individually titrated, extended release oxybutynin chloride</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Desire for Alternate Treatment</title>
          <description>Patient response to &quot;Do you wish to receive another form of treatment?&quot; (yes)</description>
          <population>Completers minus one missing value</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cochran Mantel-Haenszel procedure.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.02</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in Group Proportions</param_type>
            <param_value>-.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.086</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The estimated parameter of dispersion represents the standard error for the difference of the group proportions.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8-week treatment period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Behavioral Training</title>
          <description>Delayed voiding, urge suppression techniques, pelvic floor muscle training</description>
        </group>
        <group group_id="E2">
          <title>Drug Therapy</title>
          <description>Individually titrated, extended release oxybutynin chloride</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Results can only be generalized to men without evidence of obstruction as determined by uroflowmetry, post-void residual urine (PVR) volume, and a trial of an alpha-blocker.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kathryn L. Burgio, PhD</name_or_title>
      <organization>Birmingham VA Medical Center</organization>
      <phone>205-558-7064</phone>
      <email>kburgio@uabmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

